2026 Q1 -tulosraportti
12 päivää sitten
‧29 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 233 | - | - | ||
| 80 | - | - | ||
| 7 000 | - | - | ||
| 1 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 197 124 | 197 124 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 197 124 | 197 124 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenWe are excited to be part of the nephrology community at hashtag#ERA26 in Glasgow this week. With the updated KDIGO AKI/AKD guidelines currently in public review. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
·1 t sittenExplanation coming here. Pre-sub / Q-Sub: A Q-Submission (Q-Sub) is FDA's formal system where companies can get feedback from FDA before submitting an actual marketing authorization application (e.g., a 510(k), De Novo, or PMA). For BioPorto, this means they have sent FDA a package with information about: The NGAL test's intended use. Results from previous studies. The planned validation study. Specific questions to FDA about study design, endpoints, statistical methods, and the regulatory pathway. FDA then responds with written comments and possibly a meeting where the questions are discussed. The purpose is to reduce the risk that the company conducts an expensive study which FDA later assesses does not meet the requirements. A typical outcome can be: Positive: FDA largely accepts the proposed design. Mixed: FDA wants minor adjustments to the protocol. Negative: FDA requires a larger or different study. What happens after Q-Submission? For BioPorto, the expected process will be: Q-Submission submitted (March 31, 2026). FDA provides feedback (expected around June–July 2026). BioPorto adjusts the protocol if necessary. The validation study is conducted. Final FDA application submitted (the goal remains H1 2027). FDA evaluates the application and makes a decision. For investors, the Q-Submission feedback is often an important milestone because it provides the first relatively clear signal as to whether FDA views the proposed regulatory strategy positively. A message that FDA agrees with the study design will typically be perceived more positively than a message requiring extensive additional data. In BioPorto's case, much of the uncertainty is precisely about how extensive FDA wants the clinical documentation for the NGAL test for adult patients to be before a final application can be approved.- ·1 päivä sittenThere is really a lot of gold on the internet, you just have to bend down and pick it up. I have just found an overview of the topics that KDIGO's committee is currently in the process of agreeing on how the final document should be written. I have inserted a link where you can read about the different areas, What I am pleased about is that I have been right when I claimed that some areas will receive Grade 1 recommendations and others will receive lower ones. You can see that there are different color codes, which are the same colors used in the hospital world. If you click on the different topics, you can read about what diseases they are. So yes, they will be busy at Bioporto. Red: The absolute strongest recommendation (Grade 1) Blue: Strong recommendation (Grade 1 or strong Grade 2) Yellow: Minor or conditional recommendation (Grade 2) Green: Lowest recommendation / Baseline https://kdigo.org/guidelines/1 päivä sitten1 päivä sittenTämä kommentti on poistettu.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.
·1 päivä sittenHi 3D I have tried to do as you say. I'm getting into an almost 500-page report for the AKI area. It seems to be the one that is being prepared for publication. What's with the color codes? Once I have found the AKI report, then what? - ·28.5.There must be someone who can explain "shorting" THOROUGHLY! How does it work in practice? Who offers it and why? Is there anything regarding TA, that "meets" shorting? And if so, how? Other explanations are also welcome..,: Many of us, it seems, don't have a grasp of shorting and everything it entails. Regards. Bagerbrød·3 päivää sittenLikewise - we are still eagerly watching to see if today will push the stock up near 1.45! This is where the next "point" is, and the time interval between recent peaks COULD fit with today! I think today's closing price is exciting.
·28.5.Although it's nothing new, it's good that there are more and more small indicators of interest in the kidney area generally and Bioporto specifically. https://ugebrev.dk/life-science/bioporto-har-udviklet-et-produkt-mod-akut-nyreskade/
·29.5. · MuokattuCompletely agree. The price has shot up 50% in 2 months and now seems to have found a natural level. No doubt many have taken that profit home, but that's actually what we want. That smaller short-term shareholders who bought under 1kr sell off, so that this group will increasingly get bigger and bigger gak. Now we will probably wait a week or 2 to get feedback from FDA regarding pre submission, and if it turns out positive as expected, then surely the price can crawl a bit higher. When/if KDIGO includes Ngal as a recommendation, then I don't think it will be unlikely we will go over 2kr.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
12 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenWe are excited to be part of the nephrology community at hashtag#ERA26 in Glasgow this week. With the updated KDIGO AKI/AKD guidelines currently in public review. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all·1 t sittenExplanation coming here. Pre-sub / Q-Sub: A Q-Submission (Q-Sub) is FDA's formal system where companies can get feedback from FDA before submitting an actual marketing authorization application (e.g., a 510(k), De Novo, or PMA). For BioPorto, this means they have sent FDA a package with information about: The NGAL test's intended use. Results from previous studies. The planned validation study. Specific questions to FDA about study design, endpoints, statistical methods, and the regulatory pathway. FDA then responds with written comments and possibly a meeting where the questions are discussed. The purpose is to reduce the risk that the company conducts an expensive study which FDA later assesses does not meet the requirements. A typical outcome can be: Positive: FDA largely accepts the proposed design. Mixed: FDA wants minor adjustments to the protocol. Negative: FDA requires a larger or different study. What happens after Q-Submission? For BioPorto, the expected process will be: Q-Submission submitted (March 31, 2026). FDA provides feedback (expected around June–July 2026). BioPorto adjusts the protocol if necessary. The validation study is conducted. Final FDA application submitted (the goal remains H1 2027). FDA evaluates the application and makes a decision. For investors, the Q-Submission feedback is often an important milestone because it provides the first relatively clear signal as to whether FDA views the proposed regulatory strategy positively. A message that FDA agrees with the study design will typically be perceived more positively than a message requiring extensive additional data. In BioPorto's case, much of the uncertainty is precisely about how extensive FDA wants the clinical documentation for the NGAL test for adult patients to be before a final application can be approved.
- ·1 päivä sittenThere is really a lot of gold on the internet, you just have to bend down and pick it up. I have just found an overview of the topics that KDIGO's committee is currently in the process of agreeing on how the final document should be written. I have inserted a link where you can read about the different areas, What I am pleased about is that I have been right when I claimed that some areas will receive Grade 1 recommendations and others will receive lower ones. You can see that there are different color codes, which are the same colors used in the hospital world. If you click on the different topics, you can read about what diseases they are. So yes, they will be busy at Bioporto. Red: The absolute strongest recommendation (Grade 1) Blue: Strong recommendation (Grade 1 or strong Grade 2) Yellow: Minor or conditional recommendation (Grade 2) Green: Lowest recommendation / Baseline https://kdigo.org/guidelines/1 päivä sitten1 päivä sittenTämä kommentti on poistettu.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·1 päivä sittenHi 3D I have tried to do as you say. I'm getting into an almost 500-page report for the AKI area. It seems to be the one that is being prepared for publication. What's with the color codes? Once I have found the AKI report, then what?
- ·28.5.There must be someone who can explain "shorting" THOROUGHLY! How does it work in practice? Who offers it and why? Is there anything regarding TA, that "meets" shorting? And if so, how? Other explanations are also welcome..,: Many of us, it seems, don't have a grasp of shorting and everything it entails. Regards. Bagerbrød·3 päivää sittenLikewise - we are still eagerly watching to see if today will push the stock up near 1.45! This is where the next "point" is, and the time interval between recent peaks COULD fit with today! I think today's closing price is exciting.
- ·28.5.Although it's nothing new, it's good that there are more and more small indicators of interest in the kidney area generally and Bioporto specifically. https://ugebrev.dk/life-science/bioporto-har-udviklet-et-produkt-mod-akut-nyreskade/·29.5. · MuokattuCompletely agree. The price has shot up 50% in 2 months and now seems to have found a natural level. No doubt many have taken that profit home, but that's actually what we want. That smaller short-term shareholders who bought under 1kr sell off, so that this group will increasingly get bigger and bigger gak. Now we will probably wait a week or 2 to get feedback from FDA regarding pre submission, and if it turns out positive as expected, then surely the price can crawl a bit higher. When/if KDIGO includes Ngal as a recommendation, then I don't think it will be unlikely we will go over 2kr.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 233 | - | - | ||
| 80 | - | - | ||
| 7 000 | - | - | ||
| 1 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 197 124 | 197 124 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 197 124 | 197 124 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
12 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenWe are excited to be part of the nephrology community at hashtag#ERA26 in Glasgow this week. With the updated KDIGO AKI/AKD guidelines currently in public review. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all·1 t sittenExplanation coming here. Pre-sub / Q-Sub: A Q-Submission (Q-Sub) is FDA's formal system where companies can get feedback from FDA before submitting an actual marketing authorization application (e.g., a 510(k), De Novo, or PMA). For BioPorto, this means they have sent FDA a package with information about: The NGAL test's intended use. Results from previous studies. The planned validation study. Specific questions to FDA about study design, endpoints, statistical methods, and the regulatory pathway. FDA then responds with written comments and possibly a meeting where the questions are discussed. The purpose is to reduce the risk that the company conducts an expensive study which FDA later assesses does not meet the requirements. A typical outcome can be: Positive: FDA largely accepts the proposed design. Mixed: FDA wants minor adjustments to the protocol. Negative: FDA requires a larger or different study. What happens after Q-Submission? For BioPorto, the expected process will be: Q-Submission submitted (March 31, 2026). FDA provides feedback (expected around June–July 2026). BioPorto adjusts the protocol if necessary. The validation study is conducted. Final FDA application submitted (the goal remains H1 2027). FDA evaluates the application and makes a decision. For investors, the Q-Submission feedback is often an important milestone because it provides the first relatively clear signal as to whether FDA views the proposed regulatory strategy positively. A message that FDA agrees with the study design will typically be perceived more positively than a message requiring extensive additional data. In BioPorto's case, much of the uncertainty is precisely about how extensive FDA wants the clinical documentation for the NGAL test for adult patients to be before a final application can be approved.
- ·1 päivä sittenThere is really a lot of gold on the internet, you just have to bend down and pick it up. I have just found an overview of the topics that KDIGO's committee is currently in the process of agreeing on how the final document should be written. I have inserted a link where you can read about the different areas, What I am pleased about is that I have been right when I claimed that some areas will receive Grade 1 recommendations and others will receive lower ones. You can see that there are different color codes, which are the same colors used in the hospital world. If you click on the different topics, you can read about what diseases they are. So yes, they will be busy at Bioporto. Red: The absolute strongest recommendation (Grade 1) Blue: Strong recommendation (Grade 1 or strong Grade 2) Yellow: Minor or conditional recommendation (Grade 2) Green: Lowest recommendation / Baseline https://kdigo.org/guidelines/1 päivä sitten1 päivä sittenTämä kommentti on poistettu.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·1 päivä sittenHi 3D I have tried to do as you say. I'm getting into an almost 500-page report for the AKI area. It seems to be the one that is being prepared for publication. What's with the color codes? Once I have found the AKI report, then what?
- ·28.5.There must be someone who can explain "shorting" THOROUGHLY! How does it work in practice? Who offers it and why? Is there anything regarding TA, that "meets" shorting? And if so, how? Other explanations are also welcome..,: Many of us, it seems, don't have a grasp of shorting and everything it entails. Regards. Bagerbrød·3 päivää sittenLikewise - we are still eagerly watching to see if today will push the stock up near 1.45! This is where the next "point" is, and the time interval between recent peaks COULD fit with today! I think today's closing price is exciting.
- ·28.5.Although it's nothing new, it's good that there are more and more small indicators of interest in the kidney area generally and Bioporto specifically. https://ugebrev.dk/life-science/bioporto-har-udviklet-et-produkt-mod-akut-nyreskade/·29.5. · MuokattuCompletely agree. The price has shot up 50% in 2 months and now seems to have found a natural level. No doubt many have taken that profit home, but that's actually what we want. That smaller short-term shareholders who bought under 1kr sell off, so that this group will increasingly get bigger and bigger gak. Now we will probably wait a week or 2 to get feedback from FDA regarding pre submission, and if it turns out positive as expected, then surely the price can crawl a bit higher. When/if KDIGO includes Ngal as a recommendation, then I don't think it will be unlikely we will go over 2kr.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 233 | - | - | ||
| 80 | - | - | ||
| 7 000 | - | - | ||
| 1 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 197 124 | 197 124 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 197 124 | 197 124 | 0 | 0 |